Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2024-09-23 DOI:10.2174/0113894501323529240910015912

Mohammad Amin Habibi, Sajjad Ahmadpour, Javad Tafaroji, Seyed Mohammad Eazi, Pooryia Mineaie, Yousef Mohammadpour, Soheil Tavakolpour

{"title":"Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.","authors":"Mohammad Amin Habibi, Sajjad Ahmadpour, Javad Tafaroji, Seyed Mohammad Eazi, Pooryia Mineaie, Yousef Mohammadpour, Soheil Tavakolpour","doi":"10.2174/0113894501323529240910015912","DOIUrl":null,"url":null,"abstract":"<p><p>Remission failure and relapse numerate as one of the main problems in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAVs). The need for new agents that provide effective and safe induction accompanied by sustained remission seems to be urgent in clinical care. The efficacy and safety of rituximab (RTX) for AAVs therapy has been reported in various studies. RTX therapy offers several advantages to treating AAVs patients compared to other therapeutic approaches including reduction of Glucocorticoids (GCs) and conventional Immunosuppressive therapy (IST) usage during both the induction of remission and maintenance phases. This reduction can lead to a lower rate of serious complications making RTX therapy a safer option. It seems that RTX may provide improved clinical outcomes in these patients mediated via B-lymphocyte depletion, Proteinase 3-antineutrophilic cytoplasmic antibody (PR3-ANCA), and myeloperoxidase-antineutrophilic cytoplasmic antibody (MPO-ANCA) titers reduction. In this regard, some uncertainties have been reported to validate the association between such depletion and clinical improvement, as suggested by other sources of autoreactive B cells that did not target with RTX. Due to the prolonged B cell depletion, fixed intervals and adjusted dosage of RTX may be required in patients with AAVs. In this narrative review, we aimed to insight better understand regarding the efficacy of RTX for effective induction and sustained remission in patients with AAVs. It seems that discovering new biomarkers predicting relapse in AAVs patients can lead to future targeted therapy.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501323529240910015912","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Remission failure and relapse numerate as one of the main problems in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAVs). The need for new agents that provide effective and safe induction accompanied by sustained remission seems to be urgent in clinical care. The efficacy and safety of rituximab (RTX) for AAVs therapy has been reported in various studies. RTX therapy offers several advantages to treating AAVs patients compared to other therapeutic approaches including reduction of Glucocorticoids (GCs) and conventional Immunosuppressive therapy (IST) usage during both the induction of remission and maintenance phases. This reduction can lead to a lower rate of serious complications making RTX therapy a safer option. It seems that RTX may provide improved clinical outcomes in these patients mediated via B-lymphocyte depletion, Proteinase 3-antineutrophilic cytoplasmic antibody (PR3-ANCA), and myeloperoxidase-antineutrophilic cytoplasmic antibody (MPO-ANCA) titers reduction. In this regard, some uncertainties have been reported to validate the association between such depletion and clinical improvement, as suggested by other sources of autoreactive B cells that did not target with RTX. Due to the prolonged B cell depletion, fixed intervals and adjusted dosage of RTX may be required in patients with AAVs. In this narrative review, we aimed to insight better understand regarding the efficacy of RTX for effective induction and sustained remission in patients with AAVs. It seems that discovering new biomarkers predicting relapse in AAVs patients can lead to future targeted therapy.

查看原文本刊更多论文

利妥昔单抗治疗抗中性粒细胞胞浆抗体相关性血管炎二十年。

缓解失败和复发是抗中性粒细胞胞浆抗体相关性血管炎（AAVs）患者面临的主要问题之一。临床治疗急需新的药物，以提供有效、安全的诱导和持续缓解。已有多项研究报道了利妥昔单抗（RTX）治疗 AAVs 的有效性和安全性。与其他治疗方法相比，RTX疗法在治疗AAVs患者方面具有多项优势，包括在诱导缓解和维持治疗阶段减少糖皮质激素（GCs）和传统免疫抑制剂（IST）的使用。这种减少可降低严重并发症的发生率，使 RTX 疗法成为更安全的选择。RTX似乎可以通过B淋巴细胞耗竭、蛋白酶3-抗中性粒细胞胞浆抗体（PR3-ANCA）和髓过氧化物酶-抗中性粒细胞胞浆抗体（MPO-ANCA）滴度降低来改善这些患者的临床疗效。在这方面，有报告称，由于其他来源的自反应性 B 细胞并不是 RTX 的靶点，因此在验证这种耗竭与临床改善之间的联系时存在一些不确定性。由于 B 细胞耗竭时间较长，AAV 患者可能需要固定的 RTX 间隔和调整剂量。在这篇叙述性综述中，我们旨在深入了解RTX对AAV患者有效诱导和持续缓解的疗效。发现预测AAVs患者复发的新生物标志物似乎可以为未来的靶向治疗提供依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.